← Back to Search

Monoclonal Antibodies

Bevacizumab (Avastin) for Glioblastoma

Phase < 1
Waitlist Available
Research Sponsored by West Penn Allegheny Health System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Diagnosed w Glioblastoma grade IV, and scheduled to begin chemo radiotherapy with Avastin
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Summary

Does treatment with bevacizumab (Avastin) in combination with prior or current radiotherapy lead to optic neuropathy?

Eligible Conditions
  • Glioblastoma
  • Optic Neuropathy

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Measurement of Visual Evoked Potentials (optic nerve function and visual processing) and optic nerve function in 10 patients.
Secondary outcome measures
Number of patients diagnosed with optic neuropathy following treatment with chemo and radiation in combination with avastin treatment

Trial Design

1Treatment groups
Experimental Treatment
Group I: Bevacizumab (Avastin)Experimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bevacizumab (Avastin)
2006
Completed Phase 4
~320

Find a Location

Who is running the clinical trial?

West Penn Allegheny Health SystemLead Sponsor
35 Previous Clinical Trials
6,009 Total Patients Enrolled
~0 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top